California Practice Standards (CPJE) Prep Exam 2026 :Questions And Answers With Rationals/Graded A+ Update 100% Correct

California Practice Standards
(CPJE) Prep Exam 2026 :Questions
And Answers With
Rationals/Graded A+ Update
100% Correct
Verified Q&A | Latest 2026 Clinical & Law Test for
Pharmacy Students




PART 1: CALIFORNIA PHARMACY LAW & LEGISLATION
(Questions 1–35)

New 2025–2026 Legislative Updates




Question 1

What is the effective date of the requirement under AB 1503 that a nonresident
pharmacy must designate a California-licensed pharmacist as its pharmacist-in-
charge (PIC)?

• A. January 1, 2025
• ✅ B. July 1, 2026
• C. January 1, 2027
• D. January 1, 2030
<details> <summary>🧾 <strong>Rationale</strong></summary> AB 1503,
signed into law on October 1, 2025, requires that beginning July 1,
2026, each nonresident pharmacy must identify a California-licensed
pharmacist employed at that pharmacy to serve as its PIC. This

,applies even if the pharmacyʼs physical operations are entirely
outside California[reference:2][reference:3]. </details>




Question 2

Under SB 41, which of the following is prohibited in PBM contracts issued, amended,
or renewed on or after January 1, 2026?

• ✅ A. Spread pricing
• B. Flat pharmacy benefit management fees
• C. Rebate pass-through to payers
• D. Prior authorization for brand-name drugs
<details> <summary>🧾 <strong>Rationale</strong></summary> SB 41
prohibits spread pricing (where a PBM charges a plan more than it
reimburses the pharmacy and keeps the difference) and mandates a
passthrough pricing model effective January 1, 2026. Any contract
clause authorizing spread pricing is void by January 1, 2029,
regardless of renewal status[reference:4][reference:5]. </details>




Question 3

When must a nonresident pharmacy, under AB 1503, notify the California State
Board of Pharmacy of a change in its designated PIC?

• A. Within 7 days of the change
• ✅ B. Within 30 days of the change
• C. Within 14 days of the change
• D. Immediately upon the change
<details> <summary>🧾 <strong>Rationale</strong></summary> Under AB
1503, nonresident pharmacies must notify the Board of changes in PIC
within a specified time frame and submit to Board inspections. The
standard reporting period for such changes aligns with general
licensing requirements—within 30 days[reference:6][reference:7].
</details>




Question 4

,Under what conditions may a clinic practitioner now dispense a Schedule II
narcotic under Section 4184 of the Business and Professions Code?

• A. For chronic cancer pain management
• ✅ B. To treat acute withdrawal symptoms while arranging proper
follow-up treatment
• C. For any patient with a valid Schedule II prescription
• D. Only for hospice patients
<details> <summary>🧾 <strong>Rationale</strong></summary> Section
4184 now permits a registered clinic practitioner to dispense a
Schedule II narcotic to treat acute withdrawal symptoms only
temporarily while arranging proper follow-up treatment. This must
comply with 21 CFR §1306.07(b). The clinic must also follow
California labeling, recordkeeping, and secure storage
requirements[reference:8]. </details>




Question 5

Which of the following is TRUE about the California Medication Error Reporting
(CAMER) System required by B&P Section 4113.1?

• ✅ A. Reports must be submitted within 14 days of discovery of the error
• B. Reports are automatically disclosed to the public in real time
• C. Only hospitals are required to report medication errors
• D. The reporting deadline is 30 days after the end of each calendar quarter
<details> <summary>🧾 <strong>Rationale</strong></summary> B&P
§4113.1 requires a community pharmacy to submit a medication error
report no later than 14 days following the date of discovery.
Reports are confidential and cannot be used as the sole basis for
investigation or discipline by the Board. Registration with the
CAMER system was required by July 24, 2025, with reporting beginning
September 1, 2025[reference:9][reference:10]. </details>




Question 6

Under the new 2025 accessible labeling law (B&P Section 4076.8), a pharmacy must
provide an accessible prescription drug label at no extra cost to which patients?

• ✅ A. Patients who are blind, have low vision, or cannot read print
• B. All patients over age 65

, • C. Only Medi-Cal beneficiaries
• D. Patients who request a Spanish-language label
<details> <summary>🧾 <strong>Rationale</strong></summary> Section
4076.8 requires pharmacies to make prescription drug labels
accessible for people who are blind, have low vision, or cannot read
print. Accessible labels may include audible labels, large print,
Braille, or translated instructions and must comply with national
accessibility standards. The law does **not** apply to veterinary
prescriptions[reference:11][reference:12]. </details>




Question 7

Effective January 1, 2026, what new patient safety obligation is imposed on
hospitals with more than 100 beds?

• A. Daily medication regimen reviews by a pharmacy technician
• B. Mandatory pharmacist verification of all intravenous medications prior to
administration
• ✅ C. Pharmacist review of discharge medication lists for high-risk
patients
• D. Electronic prescribing for all controlled substances
<details> <summary>🧾 <strong>Rationale</strong></summary> A new
patient safety law effective January 1, 2026, requires pharmacists
to review discharge medication lists for high-risk patients at
hospitals greater than 100 beds. This expands pharmacist
responsibilities to ensure accurate medication profiles at both
admission and discharge to prevent medication errors during care
transitions[reference:13][reference:14]. </details>




Question 8

Under SB 339, a pharmacist may furnish up to how many days of preexposure
prophylaxis (PrEP) to a patient without a prescription?

• A. 30 days
• B. 60 days
• ✅ C. 90 days
• D. 120 days
<details> <summary>🧾 <strong>Rationale</strong></summary> SB 339
(2024) authorizes a pharmacist to furnish up to a 90-day course of